María del Rosario
García Campelo
Instituto de Salud Carlos III
Madrid, EspañaPublicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (2)
2020
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
2018
-
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)
Clinical Microbiology and Infection, Vol. 24, pp. S41-S52